US20050070537A1 - Use of dihydroimidazolones for the treatment of dogs - Google Patents

Use of dihydroimidazolones for the treatment of dogs Download PDF

Info

Publication number
US20050070537A1
US20050070537A1 US10/680,459 US68045903A US2005070537A1 US 20050070537 A1 US20050070537 A1 US 20050070537A1 US 68045903 A US68045903 A US 68045903A US 2005070537 A1 US2005070537 A1 US 2005070537A1
Authority
US
United States
Prior art keywords
dogs
treatment
awd
epilepsy
seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/680,459
Other languages
English (en)
Inventor
Chris Rundfeldt
Rita Dost
Wolfgang Loscher
Andrea Tipold
Klaus Unverferth
Hans-Joachim Lankau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Priority to US10/680,459 priority Critical patent/US20050070537A1/en
Assigned to ELBION AG reassignment ELBION AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOST, RITA, LOSCHER, WOLFGANG, RUNDFELDT, CHRIS, TIPOLD, ANDREA, UNVERFERTH, KLAUS, LANKAU, HANS-JOACHIM
Assigned to BOEHRINGER INGELHEIM VETMEDICA GMBH reassignment BOEHRINGER INGELHEIM VETMEDICA GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELBION AG
Publication of US20050070537A1 publication Critical patent/US20050070537A1/en
Assigned to BOEHRINGER INGELHEIM VETMEDICA GMBH reassignment BOEHRINGER INGELHEIM VETMEDICA GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELBION AG
Priority to US11/879,708 priority patent/US8859540B2/en
Priority to US13/616,440 priority patent/US8962617B2/en
Priority to US14/542,888 priority patent/US9469611B2/en
Priority to US15/251,022 priority patent/US20160367562A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Definitions

  • the present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or physiologically acceptable salts thereof for the treatment of epilepsy and behavioral abnormalities in dogs.
  • substituted dihydroimidazolones particularly [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or physiologically acceptable salts thereof for the treatment of epilepsy and behavioral abnormalities in dogs.
  • Seizure disorders are the most common intracranial diseases in humans and animals, particularly dogs and cats (OLIVER 1980, SCHWARTZ PORSCHE 1984, L ⁇ SCHER et al. 1985, FREY 1989). In the dog as well as in man, seizure disorders have an estimated morbidity of 0,5 1% (US Department of Health, Education and Welfare 1977, JANZ 1979, L ⁇ SCHER et al.1985, KER ⁇ NEN and RIEKKINGEN 1988, FORRESTER et al. 1989, SRENK et al. 1994).
  • Different synonyms for epilepsy are used, but describe sudden, excessive transient paroxysmal neuronal discharges in the cerebral cortex (L ⁇ SCHER 1993, JAGGY and STEFFEN 1995a).
  • Seizures are classified as either partial or generalized seizures with tonic, clonic or tonic clonic activity, with or without loss of consciousness (SCHWARTZ PORSCHE 1984).
  • Epilepsy is defined as idiopathic, when no underlying causes can be defined by clinical and pathological examinations (CUNNINGHAM 1971, DE LAHUNTA 1983, MONTGOMERY and LEE 1983, SCHWARTZ PORSCHE 1984 and CHRISMAN 1991).
  • Symptomatic epilepsy is caused either by an intracranial lesion or an extraneural, metabolic disturbance (JAGGY and STEFFEN 1995b and c, PODELL et al. 1995, JAGGY and HEYNOLD 1996).
  • idiopathic epilepsy is diagnosed in approximately 45% of cases with seizure disorders (JAGGY and STEFFEN, 1995a and c), and in 5,3 8,0% of all dogs with diseases of the nervous system (SCHWARTZ PORSCHE 1994, BERNARDINI and JAGGY 1998).
  • idiopathic epilepsy generalized seizures (80 90%) are observed (SCHWARTZ PORSCHE 1984, L ⁇ SCHER et al. 1985, BRAUND 1986, CENTER 1986, JAGGY and STEFFEN, 1995c).
  • partial seizures may occur (BREITSCHWERDT et al. 1979).
  • Newer antiepileptic drugs such as gabapentin or lamotrigine cannot be used for the treatment of epilepsy in dogs because of an insufficient half life (L ⁇ SCHER 1994), even though they are capable of successfully suppressing seizures induced by convulsant toxins like pentylenetetrazol (PTZ) in dogs.
  • PTZ pentylenetetrazol
  • a further example of such drugs is abecarnil (Loscher et al., 1990) which was shown to suppress seizures induced by PTZ but which cannot be used in the treatment of epilepsy.
  • presently available animal models can be used to test in principle whether or not a respective drug may bear the potential to become an anticonvulsant, such tests however cannot predict the clinical efficacy of the drug.
  • the problem of short half-life is even further aggravated by the fact that the gut passage in dogs is faster than in man.
  • Such new drugs should be active in the treatment of epilepsy in dogs suffering from epilepsy (i.e. patients). Such drugs should especially be also active in dogs suffering from epilepsy which could not be treated with the available medication. In addition, such drugs should have a better side effect profile, i.e. should produce fewer side effects upon treatment.
  • AWD 131 138[1 (4 chlorophenyl) 4 (4 morholinyl) 2,5 dihydro 1H imida-zol 2 one] is a new drug with anticonvulsant and anxiolytic effects (Rostock et al., 1998a d).
  • the drug was also shown to elevate the chemically induced seizure threshold in the intravenous pentylenetetrazol (PTZ) seizure test in mice and dogs.
  • PTZ pentylenetetrazol
  • 20 and 40 mg/kg p.o. increased the seizure threshold by 39 and 118%, respectively (Bialer et al., 1999).
  • this model is not a predictor of clinical activity of a drug in dogs suffering from epilepsy.
  • PTZ test drugs are administered orally and at a defined time point after drug administration, PTZ is infused i.v. until induction of first seizure like clonic twitches.
  • the dose of PTZ needed to induce such twitches, scaled to the body weight, is defined as convulsive threshold.
  • Drug effects are evaluated comparing the convulsive threshold in drug treated animals with the threshold of control experiments with vehicle treatment only. The drug effect is expressed as percent increase of convulsive threshold. While this is a model indicating some activity on seizure like behavior, PTZ does not induce epilepsy in dogs limiting the predictivity of such models for diseased animals.
  • the data do not indicate whether the test drug may produce sufficiently long lasting plasma levels to protect the animal from seizures over the day if administered not more than one to three times a day.
  • AWD 131 138 The mechanism of action of AWD 131 138 is not fully understood until now.
  • a very low affinity for the benzodiazepine binding site of the GABAA receptor was found in a broad receptor screen. Electrophysiological studies using different cloned human GABA receptor complexes indicate that AWD 131 138 acts as a low affinity partial agonist at the benzodiazepine receptor without subtype selectivity. The maximal stimulation obtained with AWD 131 138 reached only 20% of the effect of diazepam.
  • the specific receptor antagonist flumazenil was used to assess the contribution of the benzodiazepine receptor interaction for the pharmacological activity.
  • the anticonvulsive activity of AWD 131 138 could be partly antagonised, and the anxiolytic activity was fully antagonised upon co administration of flumazenil.
  • the extent of the antagonism in the seizure and anxiety test was comparable with the effect of flumazenil on the anticonvulsive and anxiolytic activity of diazepam.
  • monkeys did not identify AWD 131 138 as benzodiazepine like, as they did with midazolam and diazepam.
  • This lack of benzodiazepine like psychopharmacology was also substantiated in a self administration paradigm where AWD 131 138, unlike full benzodiazepine agonists, did not substitute for cocaine.
  • This lack of benzodiazepine like psychopharmacology may be related to the partial agonistic activity with low intrinsic activity.
  • AWD 131 138 was also found to have weak calcium channel blocking effect. This mechanism may contribute to the anticonvulsant activity (Rostock et al., 1998a d; Rundfeldt et al. 1998; Sigel et al., 1998; Yasar et al., 1999).
  • AWD 131-138 the efficacy of AWD 131-138 was evaluated in a clinical trial in epileptic dogs. More particularly, dogs with newly diagnosed idiopathic epilepsy without any pretreatment and dogs with idiopathic epilepsy, which did not responds to conventional antiepileptic medication where treated. Further, a combination treatment with AWD 131-138 and other epileptic drugs was carried out. In addition, the side effect profile of AWD 131-138 in comparison to other antiepileptic drugs was evaluated. Surprisingly, it was found that AWD 131-138 has a high potency to suppress seizures both in newly diagnosed and drug resistant epileptic dogs.
  • AWD 131-138 is a well tolerated even for long-term administration and less side effects are observed in comparison to traditional antiepileptic drugs. Furthermore, AWD 131-138 is efficient for the treatment of behavioural abnormalities in dogs, particularly those correlating with anxiety, i.e. fear behaviour such as unexpected aggression against men or environment.
  • first aspect of the present invention is the use of [1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or physiologically acceptable salts thereof as an active ingredient for the manufacture of a medicament for the treatment of epilepsy in dogs.
  • a second aspect of the invention relates to the use of AWD 131-138 or physiologically acceptable salts thereof as an active ingredient for the treatment of behavioural abnormalities in dogs.
  • the medicament of the present invention may be administered by any suitable route, e.g. parenteral, oral, nasal, pulmonal administration etc.
  • parenteral e.g., oral, nasal, pulmonal administration etc.
  • oral administration is preferred.
  • the medicament may be administered once or several times daily, e.g. 1-5 times daily. An administration of 1-3 times daily is especially preferred.
  • the dose of the active ingredient is a therapeutically effective dose, i.e. a dose, which is sufficient to ameliorate or eliminate epileptic symptoms and/or behavioural abnormalities.
  • the daily dose is preferably from 1-200 mg/kg, more preferably from 5-100 mg/kg.
  • the dose may be adapted to the need of an individual patient.
  • the active ingredient is usually administered as a pharmaceutical composition comprising the active ingredient and pharmaceutically acceptable carriers, diluents and/or adjuvants.
  • the active ingredient may also be coadministered with at least one further active ingredient if desired.
  • the further active ingredient may be selected from other antiepileptic drugs, e.g. from phenobarbital, primidone and potassium bromide.
  • the medicament of the present invention may be used for the treatment of any type of epilepsy, e.g. idiopathic or symptomatic epilepsy.
  • epilepsy e.g. idiopathic or symptomatic epilepsy.
  • idiopathic epilepsy e.g. newly diagnosed idiopathic epilepsy or already established idiopathic epilepsy, particularly drug resistant epilepsy, which cannot be treated with conventional antiepileptic dogs.
  • the medicament of the invention may also be used for the treatment of behavioural abnormalities, particularly anxiety.
  • a surprising advantage in the treatment is a reduced risk of undesirable behavioural side effects such as sedation. Further, the administration of the drug does not induce liver enzyme activity and thus does not hide other concommitant diseases.
  • dogs with idiopathic epilepsy were examined.
  • 29 dogs were treated with AWD 131 138.
  • the initial anticonvulsant treatment was started with AWD 131 138.
  • dogs with chronic epilepsy and no response to conventional treatment AWD 131 138 was added (add on treatment).
  • the first part of this investigation represents a clinical pilot study testing AWD 131 138 [1 (4 chlorophenyl) 4 (4 morholinyl) 2,5 dihydro 1H imida-zol 2 one]. 29 dogs with a history of seizure disorders were diagnosed with idiopathic epilepsy.
  • phenobarbital concentration ranged from 23.2 to 27.4 ⁇ g/mL (median 23.7, mean and standard deviation 24.8 1.8 ⁇ g/mL).
  • Grand mal seizures were observed in all cases, 15 of them developed clusters of seizures and 8 dogs were presented with either survived or acute status epilepticus. In addition to generalized seizures in 5 dogs focal seizures and in 2 cases complex partial seizures were observed (table 2). Seizure frequency in these 17 dogs ranged from six epileptic seizures per month to one seizure every six months. TABLE 2 Types of seizure in 29 dogs before treatment with AWD 131-138 number of dogs Type of seizure newly diagnosed chronic epilepsy grand mal seizures 12/2 17/17 cluster 5/12 15/17 status epilepticus — 8/17 focal seizures 3/12 5/17 complex partial seizures — 2/17 1.1.2. Dogs: Retrospective Study, Conventional Treatment
  • All dogs had at least two or more seizures before treatment. In most of the dogs (n 61) generalized seizures (grand mal type) were observed. 19 dogs had clusters in the seizure history and 7 dogs were referred in the acute phase of status epilepticus or after recovery. 13 dogs had focal seizures and in 3 dogs complex partial seizures were described (table 3).
  • the remaining four dogs were treated with primidone at daily dosages from 50 to 70 mg/kg bodyweight p.o. (median 60.0, mean and standard deviation 60.0 7.0 mg/kg). In these cases serum concentration ranged from 24.5 to 36.2 ⁇ g/mL (median 30.4, mean and standard deviation 30.4 5.9 ⁇ g/mL).
  • Potassium bromide was given at a daily dosage of 40 60 mg/kg bodyweight p.o. (median 41, mean and standard deviation 42.6 5.4 mg/kg). Bromide concentration ranged from 0.6 to 1.4 mg/mL (median 0.9, mean and standard deviation 1.0. 0.3 mg/mL; therapeutic range 1.0 2.0 mg/mL, established by PODELL and FENNER 1993).
  • the project was designed to be a prospective study over a period of 7 to 9 months. In case of death the observation period was shorter (see results). History of the seizure frequency, severity and duration, age of onset of the first seizure and previous or ongoing antiepileptic treatment were recorded for each case (see 1.1). Epileptic seizures were categorized based on the owner's observations and video monitoring (table 2) (HEYNOLD et al. 1997, BERNARDINI and JAGGY 1998, BERENDT and GRAM 1999, THOMAS 2000).
  • idiopathic epilepsy was based on normal physical and neurologic findings and normal special examinations. All dogs had a standardized physical and neurological examination (JAGGY and TIPOLD 1999). Bloodwork included in all cases hematology (red, white and differential cell count) and blood chemistry (alanine transferase (ALT), alkaline phosphatase (AP), glutamate dehydrogenase (GLDH), ammonia, glucose, urea, creatinine, total serum bilirubin, cholesterol, serum albumin, calcium, sodium and potassium). Plasma concentrations of phenobarbital (ALOMED, Radolfzell) were analyzed by an external laboratory.
  • AWD 131 138 treatment started in all cases with a dosage of 5 mg/kg bodyweight p.o. twice a day for one week. In the second week the dosage was increased to 10 mg/kg in every dog. If seizures were still observed the dosage of AWD 131 138 was increased up to 30 mg/kg bodyweight twice a day (table 5).
  • the first follow up examination was performed three weeks after therapy with AWD 131 138 was started, followed by examinations at 6 or 8 week intervals or depending on individual occurrence of seizures.
  • a clinical and neurological examination including blood work was done.
  • all owners kept a log book with precise description of occurring seizures, including frequency, duration and severity, behavioral changes, other medication and possible observed adverse effects.
  • the plasma concentration of AWD 131 138 and its metabolite were measured.
  • a pharmacokinetic study was performed at the beginning of treatment in 2 dogs with AWD 131 138 monotherapy and in 4 dogs with a combination therapy of AWD 131 138 and phenobarbital or primidone. All 6 dogs received 5 mg/kg bodyweight AWD 131 138. Blood was taken 3 times every 2 hours. The plasma concentration of AWD 131 138 and its metabolite were measured using HPLC/mass spectrometry. The same method was used as a compliance control during the follow up examinations. Blood was taken two and twelve hours after oral administration of AWD 131 138.
  • the statistical software package WinSTAT ⁇ for EXCEL ⁇ was used to calculate descriptive parameters in each group such as mean, median value and standard deviation of age, age of seizure onset, age at the beginning of treatment, the dosages of phenobarbital or primidone including the serum concentration.
  • seizure frequency Prior to presentation seizure frequency ranged from eight seizures per month to one seizure every eight months (median 1.6).
  • seizure frequency per month varied from complete control of seizures to 9 seizure events per month (median 0.71) (table 7).
  • Table 7 In 9 of these 12 dogs a seizure reduction was observed.
  • the improvement of seizure frequency in these dogs was statistically significant (p ⁇ 0.05).
  • the percentage of seizure reduction in responders was 49,8% given as mean value (table 7).
  • seizure frequency per month varied during unsuccessful treatment with phenobarbital or primidone from eight seizures per month to one respectively four seizures every six months (median 1.9).
  • seizure frequency per month ranged from free of seizures to 9 seizure events (median 2.0) (table 8).
  • In 10 of these 17 dogs a seizure reduction was observed.
  • the improvement of seizure frequency in these dogs was statistically significant (p ⁇ 0.05).
  • the percentage of seizure reduction in responders was 47,2% given as mean value (table 8).
  • the percentage of seizure reduction in responders was 59.7% given as mean value (table 8). In 5 dogs (42%) the reduction of seizure frequency was higher than 50%, 5 further dogs were considered to be non responders. 6 dogs of these group either died or were euthanized in status epilepticus on the owners request.
  • Non-responders were defined as dogs either showing no decrease in seizure frequency or an increase i seizure frequency during treatment. Seizue frequencies are given as median group values, percent reduction of seizures is given as mean ⁇ SEM (standard error of mean). ” n” is the number of epileptic dogs per group. Significant differences in values before and during treatment are indicated by asterisk (P ⁇ 0.05). Comparison of treatment groups by Fisher's exact test did not indicate any significant difference between the antiepileptic efficacy of the two drugs.
  • Phenobarbital/Primidone Phenobarbital/Primidone AWD 131-138 Potassium bromide Before During Before During n Treatment Treatment n Treatment Treatment Seizure freqency (seizures/month) All dogs 17 1.9 2.0 12 3.0 1.9 Without nonresponders 10 2.4 1.1* 7 3.0 0.8* % reduction of seizures 10 47.2 ⁇ 8.8 7 59.7 ⁇ 5.9 in responders Number of dogs with 6/17 (35%) 5/12 >50% reduction of seizures (42%) Number of seizure-free dogs 1/17 (8%) 0/12 Number of nonresponders 6/17 (35%) 5/12 (42%) 2.2. Duration and Severity of Seizure Activity 2.2.1. Pilot Study: AWD 131 138 Treatment 2.2.1.1. Newly Diagnosed Dogs
  • the duration of the ictus prior to presentation varied from half a minute to 10 minutes (median 3.0 minutes) (table 9). The average time in most patients was 2 to 3 minutes.
  • the average time in most patients was 2 to 3 minutes.
  • During monotherapy with AWD 131 138 ictus duration ranged also from half a minute to 10 minutes but with a median value of 2.5 minutes. In five cases the duration of the ictus was decreased between 12 and 50% (mean 38%).
  • a postictal phase with behavior changes was observed in all twelve dogs before presentation and ranged between 10 minutes to 24 hours. In four dogs the postictal time was shortened for 50 to 75%.
  • a decrease of seizure severity was described subjectively by nine of 12 owners. Prior to presentation all dogs had grand mal seizures (table 2), which extended in five dogs to clusters. During AWD 131 138 treatment two dogs only developed focal seizures. One dog never got clusters, the other 4 dogs had a reduced seizure number per cluster (mean 45.3% reduction).
  • Grand mal seizure duration in seventeen dogs during the conventional monotherapy with phenobarbital or primidone ranged from 30 seconds to 10 minutes (median 2.0 minutes) (table 9). After supplementation with AWD 131 138 duration of seizures was slightly diminished from 30 seconds to 5 minutes with a median of 2.0 minutes. The time of the ictus was decreased in 3 dogs from 40 to 50%.
  • the duration of the ictus before treatment varied from 0.5 to 10 minutes (median 4.0 minutes) (table 9). The average time in most cases was 2 to 3 minutes. During phenobarbital application the duration of the main seizure episodes varied also from 0.5 minutes to 10 minutes but with a median value of 5.0 minutes. In only 4 dogs, which did not become seizure free, a shortening of the observed ictus from 33 to 50% occurred.
  • a postictal phase with behavior changes was observed in 39 dogs before treatment and ranged between ten minutes to twenty four hours (mean 3.5 hours). During phenobarbital application the postictal phase was reduced to 5 minutes to 24 hours (mean 3 hours). This time period was abbreviated in 8 dogs from 30 to 65% (mean 43%).
  • ictus prior presentation ranged from 0.5 minutes to 10 minutes (median 1.5 minutes) (table 9). In most cases the average time was 2 to 3 minutes.
  • ictus duration varied from 0.5 minutes to 10 minutes (median of 1.0 minutes) and decreased only in 2 dogs (30%).
  • Postictal signs were observed in twenty two dogs before presentation and ranged between 15 minutes to 48 hours (mean 5 hours). During primidone application the postictal phase lasted for 10 minutes to 48 hours (mean 4.5 hours). The duration of the postictal phase was shortened in 5 dogs from 25 to 65% (mean 40%).
  • ictus duration varied from 1.0 minute to 13 minutes (median 3.0 minutes) (table 9). The average time in most cases was 1 to 3 minutes. After potassium bromide supplementation the duration of the ictus varied from 1.0 minute to 10 minutes (median 2.0 minutes). The duration of the ictus decreased in 3 dogs from 40 to 50%.
  • Postictal signs were observed in eleven dogs before presentation and ranged between half an hour to 24 hours (mean 6.0 hours). During combination therapy with potassium bromide the postictal phase varied from 15 minutes to 24 hours (mean 5.5 hours). The duration of postictal phase was abbreviated in two dogs (50 and 75%).
  • AWD 131 138 was measured in plasma samples two, four and six hours after application. The results are summarized in table 10. The initial dosage of AWD 131 138 was 5 mg/kg bodyweight p.o. in all cases.
  • AWD 131-138 plasma concentration in ng/mL Time after application 2 hours 4 hours 6 hours
  • AWD 131-138 monotherapy Dog 1 720.0 702.7 229.5 Dog 2 2579.2 1461.0 709.0
  • AWD 131-138 phenobarbital combination therapy Dog 3 23.27 Bld bld Dog 4 1019.5 173.8 19.5
  • AWD 131-138 primidone combination therapy Dog 5 1520.5 1021.5 448.1 Dog 6 2392.3 2438.7 1289.0
  • AWD 131 138 plasma concentration were measured for the first time three weeks after the beginning of the treatment 2 and 12 hours after application.
  • the concentration ranged in eleven cases 2 hours after oral application between 53.28 and 8619.4 ng/mL (median 2585.0, mean and standard deviation 3356.3 3290.3 ng/mL) ( FIG. 1 and 2 ).
  • the AWD 131 138 dosage varied between 10 mg/kg bodyweight in eight dogs, 15 mg/kg bodyweight in two dogs and 20 mg/kg bodyweight twice a day in one dog.
  • Plasma concentrations at this time point 12 hours after application ranged in all twelve dogs between 5.4 and 1139.2 ng/mL (median 218.1, mean and standard deviation 377.5 406.0 ng/mL) ( FIG.
  • the plasma concentration of the seventeen dogs with chronic epilepsy and add on treatment ranged between 279.6 to 10613.7 ng/mL (median 2992.4, mean and standard deviation 3896.1. 3339.2 ng/mL) after 2 hours of application ( FIG. 2 ).
  • the AWD 131 138 dosage varied between 10 mg/kg bodyweight in fifteen dogs and 15 mg/kg bodyweight in two dogs twice a day.
  • Plasma concentration after 12 hours of application ranged between 7.57 and 5873.04 ng/mL (median 179.3, mean 644.0). Further control examinations were also performed in this group at different time points.
  • the plasma concentrations varied between 156.46 and 26 710.58 ng/mL two hours after oral application ( FIG. 1 ). However, the therapeutic range of AWD 131 138 is not known until this time point. There was no correlation between plasma concentration and seizure frequency ( FIG. 2 and 3 ).
  • AWD 131 138 a new antiepileptic and anxiolytic drug, was evaluated in this clinical pilot study in dogs with newly diagnosed or chronic idiopathic epilepsy to test the anticonvulsant effectiveness of this substance. Similar to human epilepsy animals may be selected into dogs with pharmacoresistant seizures and dogs with pharmacosensitive seizures (L ⁇ SCHER, 1997).
  • Plasma concentrations of AWD 131 138 were measured for two purposes: to control pharmacokinetics after a single dose of oral application of the new substance in affected dogs and to control the owners compliance during the study. Pharmacokinetics revealed a high variation of plasma concentrations, probably caused by the different distribution of the substance in different tissues. The same variability in plasma concentrations also occurred after 3 weeks of the medication with AWD 131 138 and at different time points. An interesting finding was that in dogs with chronic epilepsy and treatment with phenobarbital supplemented with AWD 131 138 the lowest values were found. Further studies should be performed to evaluate, if a certain interaction between phenobarbital and AWD 131 138 occurs leading to low plasma concentrations. Plasma concentration did not correlate with the seizure frequency. However, in dogs with slow increase of the AWD 131 138 dosage seizure reduction occurred only with a certain delay. Since no side effects were observed a more aggressive treatment schedule could be introduced in future experiments and enhance the effectiveness in dogs with idiopathic epilepsy.
  • AWD 131 138 has a potent anticonvulsant effect in dogs with idiopathic epilepsy.
  • AWD 131 138 is equipotent to conventional antiepileptic drugs such as phenobarbital or primidone. Chronic administration is well tolerated and less side effects were observed in comparison to traditional antiepileptic drugs.
  • These positive results support the development of AWD 131 138 as an effective anti-epileptic drug for the treatment of dogs.
  • Unexpectedly the very low affinity and partial agonistic activity to the benzodiazepine receptor translated into anticonvulsant activity with a reduced potential for side effects in patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/680,459 2002-10-10 2003-10-06 Use of dihydroimidazolones for the treatment of dogs Abandoned US20050070537A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/680,459 US20050070537A1 (en) 2002-10-10 2003-10-06 Use of dihydroimidazolones for the treatment of dogs
US11/879,708 US8859540B2 (en) 2002-10-10 2007-07-18 Use of dihydroimidazolones for the treatment of dogs
US13/616,440 US8962617B2 (en) 2002-10-10 2012-09-14 Use of dihydroimidazolones for the treatment of dogs
US14/542,888 US9469611B2 (en) 2002-10-10 2014-11-17 Use of dihydroimidazolones for the treatment of dogs
US15/251,022 US20160367562A1 (en) 2002-10-10 2016-08-30 Use of dihydroimidazolones for the treatment of dogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
US10/680,459 US20050070537A1 (en) 2002-10-10 2003-10-06 Use of dihydroimidazolones for the treatment of dogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/879,708 Division US8859540B2 (en) 2002-10-10 2007-07-18 Use of dihydroimidazolones for the treatment of dogs

Publications (1)

Publication Number Publication Date
US20050070537A1 true US20050070537A1 (en) 2005-03-31

Family

ID=32094042

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/680,459 Abandoned US20050070537A1 (en) 2002-10-10 2003-10-06 Use of dihydroimidazolones for the treatment of dogs
US11/879,708 Active 2025-12-18 US8859540B2 (en) 2002-10-10 2007-07-18 Use of dihydroimidazolones for the treatment of dogs
US13/616,440 Expired - Lifetime US8962617B2 (en) 2002-10-10 2012-09-14 Use of dihydroimidazolones for the treatment of dogs
US14/542,888 Expired - Lifetime US9469611B2 (en) 2002-10-10 2014-11-17 Use of dihydroimidazolones for the treatment of dogs
US15/251,022 Abandoned US20160367562A1 (en) 2002-10-10 2016-08-30 Use of dihydroimidazolones for the treatment of dogs

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/879,708 Active 2025-12-18 US8859540B2 (en) 2002-10-10 2007-07-18 Use of dihydroimidazolones for the treatment of dogs
US13/616,440 Expired - Lifetime US8962617B2 (en) 2002-10-10 2012-09-14 Use of dihydroimidazolones for the treatment of dogs
US14/542,888 Expired - Lifetime US9469611B2 (en) 2002-10-10 2014-11-17 Use of dihydroimidazolones for the treatment of dogs
US15/251,022 Abandoned US20160367562A1 (en) 2002-10-10 2016-08-30 Use of dihydroimidazolones for the treatment of dogs

Country Status (28)

Country Link
US (5) US20050070537A1 (fr)
EP (3) EP2036563A1 (fr)
JP (4) JP4694202B2 (fr)
KR (2) KR101110587B1 (fr)
CN (2) CN101890019A (fr)
AR (1) AR041573A1 (fr)
AT (1) ATE418337T1 (fr)
AU (2) AU2003273978B2 (fr)
BE (1) BE2013C046I2 (fr)
BR (1) BR0315225A (fr)
CA (2) CA2727722C (fr)
CY (3) CY1109961T1 (fr)
DE (1) DE60325496D1 (fr)
DK (2) DK1553952T3 (fr)
ES (2) ES2908453T3 (fr)
FR (2) FR13C0044I2 (fr)
HK (1) HK1085920A1 (fr)
HR (3) HRP20090667B1 (fr)
HU (2) HUS1300035I1 (fr)
LU (1) LU92238I2 (fr)
MX (1) MXPA05003663A (fr)
NZ (1) NZ539864A (fr)
PL (2) PL214702B1 (fr)
PT (2) PT1553952E (fr)
SI (2) SI1553952T1 (fr)
TW (2) TWI424849B (fr)
WO (1) WO2004032938A1 (fr)
ZA (1) ZA200502245B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032863A1 (en) * 2003-07-11 2005-02-10 Barbara Langen Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
US20080027057A1 (en) * 2002-10-10 2008-01-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
ES2715050T3 (es) 2014-05-28 2019-05-31 Toa Eiyo Ltd Derivados de tropano sustituidos
WO2016044370A1 (fr) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Composition cannabinoïde et méthode de traitement de la douleur
EP3247359A4 (fr) 2015-01-25 2018-08-08 India Globalization Capital, Inc. Compositions et procédés de traitement de troubles épileptiques
WO2017027651A1 (fr) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Méthode et composition pour traiter la cachexie et les troubles de l'alimentation
CA3027862A1 (fr) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Methode et composition pour traiter des troubles epileptiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19532668A1 (de) 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
JP2002507211A (ja) * 1997-06-26 2002-03-05 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ジヒドロホノキオール組成物の合成
JP4669095B2 (ja) 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
ATE540943T1 (de) 2002-03-07 2012-01-15 Boehringer Ingelheim Pharma 3-ä(2-ää4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoümethylü-1-methyl-1h-benzimidazol-5- carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester methansulfonat
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080027057A1 (en) * 2002-10-10 2008-01-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
US8859540B2 (en) 2002-10-10 2014-10-14 Boehringer Ingelheim Vetmedica Gmbh Use of dihydroimidazolones for the treatment of dogs
US8962617B2 (en) 2002-10-10 2015-02-24 Boehringer Ingelheim Vetmedica Gmbh Use of dihydroimidazolones for the treatment of dogs
US9469611B2 (en) 2002-10-10 2016-10-18 Boehringer Ingelheim Vetmedica Gmbh Use of dihydroimidazolones for the treatment of dogs
US20050032863A1 (en) * 2003-07-11 2005-02-10 Barbara Langen Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
US10420774B2 (en) 2014-03-24 2019-09-24 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
PT2845594T (pt) 2022-03-09
CY1109961T1 (el) 2014-09-10
SI2845594T1 (sl) 2022-04-29
US20130065898A1 (en) 2013-03-14
PL397320A1 (pl) 2012-02-13
MXPA05003663A (es) 2005-06-08
DK2845594T3 (da) 2022-03-07
JP2016104817A (ja) 2016-06-09
ZA200502245B (en) 2005-11-30
JP4694202B2 (ja) 2011-06-08
CY1125103T1 (el) 2023-01-05
CN1726040B (zh) 2010-05-12
TW201010706A (en) 2010-03-16
WO2004032938A1 (fr) 2004-04-22
TWI424849B (zh) 2014-02-01
US8859540B2 (en) 2014-10-14
AU2009225322A1 (en) 2009-11-05
HUS2200036I1 (hu) 2022-08-28
EP2845594B1 (fr) 2022-02-23
JP6249812B2 (ja) 2017-12-20
JP2011068685A (ja) 2011-04-07
CN101890019A (zh) 2010-11-24
HRP20200207A2 (hr) 2020-07-24
CY2013031I1 (el) 2015-11-04
BE2013C046I2 (fr) 2022-08-09
CN1726040A (zh) 2006-01-25
SI1553952T1 (sl) 2009-04-30
KR20050056237A (ko) 2005-06-14
NZ539864A (en) 2007-11-30
PL374603A1 (en) 2005-10-31
HUS1300035I1 (hu) 2017-10-30
ATE418337T1 (de) 2009-01-15
EP1553952B1 (fr) 2008-12-24
DE60325496D1 (de) 2009-02-05
DK1553952T3 (da) 2009-04-20
FR13C0044I2 (fr) 2014-03-07
HRP20050322B1 (hr) 2013-12-06
PL238776B1 (pl) 2021-10-04
US9469611B2 (en) 2016-10-18
EP2036563A1 (fr) 2009-03-18
AR041573A1 (es) 2005-05-18
US20080027057A1 (en) 2008-01-31
JP2014080449A (ja) 2014-05-08
ES2316808T3 (es) 2009-04-16
LU92238I9 (fr) 2019-01-09
PT1553952E (pt) 2009-02-10
CA2501772C (fr) 2011-08-23
HK1085920A1 (en) 2006-09-08
EP1553952A1 (fr) 2005-07-20
CA2727722A1 (fr) 2004-04-22
PL214702B1 (pl) 2013-09-30
EP2845594A1 (fr) 2015-03-11
HRP20090667B1 (hr) 2021-06-11
TW200503726A (en) 2005-02-01
HRP20050322A2 (en) 2006-05-31
LU92238I2 (fr) 2013-09-03
AU2003273978B2 (en) 2009-07-23
JP2006503873A (ja) 2006-02-02
US20160367562A1 (en) 2016-12-22
KR20110063843A (ko) 2011-06-14
US20150072983A1 (en) 2015-03-12
US8962617B2 (en) 2015-02-24
CA2501772A1 (fr) 2004-04-22
HRP20090667A2 (hr) 2010-07-31
CA2727722C (fr) 2013-05-28
ES2908453T3 (es) 2022-04-29
FR13C0044I1 (fr) 2013-08-30
TWI324067B (en) 2010-05-01
AU2003273978A1 (en) 2004-05-04
FR22C1033I1 (fr) 2022-09-09
BR0315225A (pt) 2005-08-23
KR101110587B1 (ko) 2012-02-15
CY2013031I2 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
US9469611B2 (en) Use of dihydroimidazolones for the treatment of dogs
Tipold et al. Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs
JP7312116B2 (ja) 外傷後ストレス障害の治療用の製剤
US20220378706A1 (en) Pharmaceutical composition comprising pde9 inhibitor
AU2012258470B2 (en) Use of dihydroimidazolones for the treatment of epilepsy in dogs
NZ554935A (en) Use of dihydroimidazolones for the treatment of behavioural abnormalities in dogs
Meldrum Anticonvulsant drugs with new mechanisms of action

Legal Events

Date Code Title Description
AS Assignment

Owner name: ELBION AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUNDFELDT, CHRIS;DOST, RITA;LOSCHER, WOLFGANG;AND OTHERS;REEL/FRAME:014233/0881;SIGNING DATES FROM 20031013 TO 20031028

AS Assignment

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELBION AG;REEL/FRAME:016884/0534

Effective date: 20050218

AS Assignment

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELBION AG;REEL/FRAME:016884/0578

Effective date: 20050218

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION